CTLT:NYSE (USA) Also trade in: Germany

Catalent Inc

$ 43.97 1.22 (2.85%)
Volume: 1,422,031 Avg Vol (1m): 836,810
Market Cap $: 6.40 Bil Enterprise Value $: 8.40 Bil
P/E (TTM): 44.88 P/B: 4.06
Earnings Power Value 3.71
Net Current Asset Value -12.41
Tangible Book -3.02
Projected FCF 14
Median P/S Value 34.98
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 5/10

Current vs industry vs history
Cash-to-Debt 0.10
Equity-to-Asset 0.35
Debt-to-Equity 1.41
Debt-to-EBITDA 4.53
Interest Coverage 2.60
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.85
DISTRESS
GREY
SAFE
Beneish M-Score -2.34
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 7.24%
WACC 11.11%

Profitability & Growth : 7/10

Current vs industry vs history
Operating Margin % 11.86
Net Margin % 5.48
ROE % 10.90
ROA % 3.04
ROC (Joel Greenblatt) % 17.01
3-Year Total Revenue Growth Rate 10.40
3-Year Total EBITDA Growth Rate 8.20
3-Year EPS w/o NRI Growth Rate -28.90
N/A

» CTLT's 30-Y Financials

Financials (Next Earnings Date: 2019-05-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:CTLT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare BOM:500124 TSX:VRX SHSE:603858 BOM:500257 TSX:WEED SHSE:600566 NSE:AUROPHARMA HKSE:00867 SZSE:000513 SZSE:002773 BOM:532321 SZSE:300142 SHSE:600521 TSE:4530 OHEL:ORNBV TSE:4516 SZSE:000423 TSX:ACB TSE:4506 NSE:DIVISLAB
Traded in other countries 0C8.Germany
Address 14 Schoolhouse Road, Somerset, NJ, USA, 08873
Catalent is a specialty and generic drug manufacturing company. The company focuses on advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The vast majority of Catalent's sales are generated in the United States, followed by Europe and the rest of the world. Most of the company's sales are derived from branded drug products. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Ratios

Current vs industry vs history
PE Ratio (TTM) 44.88
Forward PE Ratio 21.41
N/A
PE Ratio without NRI 44.88
Price-to-Owner-Earnings 44.93
PB Ratio 4.06
PS Ratio 2.45
Price-to-Free-Cash-Flow 55.09
Price-to-Operating-Cash-Flow 21.41
EV-to-EBIT 30.68
EV-to-EBITDA 17.26
EV-to-Revenue 3.34
PEG Ratio 20.05
Current Ratio 2.08
Quick Ratio 1.63
Days Inventory 47.58
Days Sales Outstanding 80.88
Days Payable 39.29

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -2.40

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 3.14
Price-to-Median-PS-Value 1.26
Earnings Yield (Joel Greenblatt) % 3.30
Forward Rate of Return (Yacktman) % 3.43

More Statistics

Revenue (TTM) (Mil) $ 2,488
EPS (TTM) $ 0.98
Beta 1.99
Volatility % 39.08
52-Week Range $ 29.23 - 46.43
Shares Outstanding (Mil) 145.71

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N